StockNews.AISignal intelligence
Insmed Incorporated · NASDAQ · Healthcare
Browse public INSM signals with their source context and measured market impact. Open any signal for its permanent analysis page.
Insmed reported 12-month PALM-PAH data for TPIP, showing sustained efficacy and similar gains for continuers and placebo crossovers. Notable metrics include 6MWD gains of 55.7m vs 54.1m, ~60% NT-proBNP reduction, and ~65% achieving Refined Low Risk; safety signals were not identified, supporting continued Phase 3 development.
View signal analysisInsmed announced positive 12-month data from TPIP’s open-label extension in PAH, showing sustained improvements in 6MWD, NT-proBNP, WHO Functional Class, and REVEAL Lite 2.0 risk scores, with placebo-crossed patients achieving similar outcomes. Safety remained acceptable up to 1,280 µg daily; PALM-PAH Phase 3 is underway, potentially accelerating TPIP’s approval pathway.
View signal analysisInsmed has announced the discontinuation of its brensocatib development program for hidradenitis suppurativa after the Phase 2b CEDAR study failed to meet efficacy endpoints. This failure may impact investor confidence and lead to a reevaluation of the company's pipeline and future growth prospects.
View signal analysisInsmed's recent ENCORE study results for Arikayce demonstrate strong effectiveness against Mycobacterium avium complex lung infections. Analysts remain optimistic, maintaining bullish ratings and setting price targets indicating substantial upside potential for the stock by late 2026 when the FDA filing occurs.
View signal analysisInsmed projects significant revenue growth through 2026. Brinsupri shows strong early traction with $172.7M revenue in 2025. Arikayce forecasts suggest sales could exceed $470 million in 2026. Multiple trials underway, with key results expected in 2026 for Arikayce. Promising drug pipeline targets various diseases, including ALS and muscular dystrophy.
View signal analysisINSM stock dropped 15.28% after trial failure announcement. Phase 2b study of brensocatib did not meet efficacy endpoints. Insmed has halted brensocatib's development for CRSsNP immediately. FDA approved Brinsupri, but brensocatib's failure impacts sentiment. Analysts remain positive on Insmed's other programs, despite setbacks.
View signal analysis